human
immunodefici
viru
type
major
caus
acquir
immunodefici
syndrom
aid
infect
million
peopl
worldwid
end
accord
unit
nation
joint
programm
hivaid
unaid
report
signific
success
achiev
treatment
sinc
introduct
highli
activ
antiretrovir
therapi
haart
current
antiretrovir
therapi
three
four
drug
use
combin
target
multipl
step
life
cycl
includ
viral
revers
transcriptas
integras
proteas
viral
entri
fusion
viral
entri
fusion
inhibitor
attract
agent
therapi
last
sever
decad
great
progress
made
understand
mechan
entri
host
cell
involv
bind
viral
glycoprotein
cellular
receptor
subsequ
reconfigur
allow
interact
cellular
coreceptor
ie
interact
follow
addit
conform
chang
viral
envelop
result
exposur
transmembran
protein
ultim
drive
fusion
viral
envelop
host
membran
date
antagonist
maraviroc
mvc
fusion
inhibitor
target
enfuvirtid
approv
clinic
use
mani
inhibitor
target
variou
stage
viral
entri
still
develop
polyoxometal
pom
earli
transit
metal
cluster
link
oxygen
atom
pom
exhibit
great
divers
structur
wide
use
catalyst
materi
scienc
medicin
two
basic
structur
pom
keggin
dawson
attract
attent
owe
antivir
properti
pom
shown
activ
broad
rang
dna
rna
virus
includ
influenza
b
sever
acut
respiratori
syndrom
coronaviru
sarsv
respiratori
syncyti
viru
dengu
viru
pom
known
end
hivaid
clinic
trial
compound
fail
due
unaccept
advers
effect
minor
benefit
sinc
sever
group
synthes
identifi
number
new
gener
pom
improv
potenc
reduc
toxic
although
mechan
remain
unclear
previous
identifi
antihiv
activ
number
keggin
pom
deriv
present
work
evalu
potenc
mechan
action
keggin
polyoxometal
cambridg
crystallograph
data
centr
ccdc
prevent
entri
tzmbl
cell
obtain
nation
institut
health
aid
reagent
repositori
cultur
dulbecco
modifi
eagl
medium
dmem
gibco
shanghai
china
supplement
vv
fetal
bovin
serum
fb
hyclon
shanghai
china
lglutamin
uml
penicillinstreptomycin
cell
human
tcell
line
purchas
american
type
cultur
collect
atcc
maintain
rpmi
gibco
supplement
vv
fetal
bovin
serum
lglutamin
uml
penicillinstreptomycin
peripher
blood
mononuclear
cell
pbmc
isol
three
healthi
donor
cultur
complet
rpmi
medium
fetal
bovin
serum
lglutamin
uml
penicillinstreptomycin
ngml
hiv
env
clone
nih
nih
nih
nih
nih
nih
nih
nih
backbon
vector
nih
obtain
nation
institut
health
aid
reagent
repositori
env
nih
env
nih
env
nih
env
nih
kindli
provid
dr
lei
yu
shenzhen
cdc
china
strain
kindli
gift
institut
biophys
chines
academi
scienc
pcmvvsvg
envelop
vector
kindli
gift
dr
rui
pedro
galao
king
colleg
london
london
uk
synthes
dr
yan
hong
previous
describ
structur
inform
deposit
cambridg
crystallograph
data
centr
ccdc
aqueou
stock
solut
mm
store
cell
count
assay
assay
dojindo
shanghai
china
perform
determin
cell
viabil
tzmbl
cell
treatment
cell
seed
plate
treat
serial
dilut
rang
h
end
experi
cell
incub
solut
h
measur
nm
use
multimod
plate
reader
perkinelm
waltham
mi
usa
cytotox
valu
calcul
cytotox
concentr
use
graphpad
prism
softwar
version
graphpad
softwar
inc
la
jolla
ca
usa
select
index
calcul
half
maxim
inhibitori
concentr
micronucleu
test
conduct
previous
describ
briefli
male
kunm
mice
old
g
obtain
beij
vital
river
laboratori
anim
technolog
co
ltd
beij
china
anim
acclim
week
randomli
alloc
follow
group
five
mice
vehicl
control
normal
salin
mgkg
lowdos
mgkg
middos
mgkg
highdos
posit
control
cyclophosphamid
cp
mgkg
mice
administr
intragastr
salin
intraperiton
cp
day
three
day
mice
sacrif
h
post
last
administr
bilater
femur
separ
bone
marrow
cell
collect
aforement
femur
fetal
bovin
serum
centrifug
g
min
smear
onto
slide
slide
airdri
fix
submerg
methanol
min
follow
giemsa
stain
min
slide
randomli
code
count
magnif
data
express
ratio
immatur
erythrocyt
polychromat
erythrocyt
pce
total
erythrocyt
pce
normochromat
erythrocyt
nce
count
least
erythrocyt
number
micronucl
mn
pce
pce
studi
carri
approv
anim
ethic
committe
china
academi
chines
medic
scienc
approv
code
activ
perform
use
tzmbl
assay
envpseudotyp
virus
prepar
cotransfect
cell
env
express
plasmid
use
fugen
transfect
reagent
promega
madison
wi
usa
recombin
virus
collect
cell
supernat
centrifug
rpm
min
store
liquid
nitrogen
titer
envpseudotyp
virus
examin
tissu
cultur
infect
dose
assay
use
reedmuench
method
late
tzmbl
cell
seed
plate
infect
viru
dilut
diethylaminoethanol
deae
dextran
sigma
shanghai
china
presenc
two
day
infect
infect
virus
evalu
use
brightglo
luciferas
assay
kit
promega
manufactur
instruct
luciferas
activ
analyz
use
multimod
plate
reader
perkinelm
express
term
rel
luciferas
unit
rlu
half
maxim
inhibitori
concentr
calcul
inhibitori
concentr
use
graphpad
prism
softwar
assess
activ
viru
entri
vesicular
stomat
viru
glycoprotein
vsvg
pseudotyp
virus
produc
cotransfect
cell
pcmvvsvg
plasmid
viru
titer
determin
assay
tzmbl
cell
infect
either
envpseudotyp
virus
equal
amount
vsvgpseudotyp
virus
addit
indic
dose
incub
h
luciferas
activ
measur
brightglo
luciferas
assay
kit
promega
compar
differ
env
vsvgmediat
viru
entri
inhibit
human
tcell
line
cell
infect
presenc
indic
concentr
posit
control
zidovudin
azt
twohour
postinfect
cell
wash
phosphatebuff
salin
pb
transfer
plate
cultur
incub
medium
replac
day
analyz
day
cultur
supernat
harvest
quantifi
use
enzymelink
immunosorb
assay
elisa
vironostika
antigen
elisa
kit
biomerieux
lyon
franc
peripher
blood
mononuclear
cell
isol
three
healthi
blood
donor
use
ficol
gradient
ge
healthcar
chicago
il
usa
pbmc
prestimul
cona
sigma
densiti
cellsml
day
activ
pbmc
wash
twice
pb
maintain
cultur
medium
contain
human
recombin
ngml
peprotech
inc
suzhou
china
viral
infect
pbmc
incub
increas
concentr
azt
h
infect
cell
wash
twice
ad
plate
contain
fresh
azt
solut
day
postinfect
half
medium
remov
replac
fresh
medium
contain
azt
supernat
collect
day
infect
test
antigen
vironostika
antigen
elisa
kit
azt
use
posit
control
timeofaddit
studi
conduct
use
singleround
replic
assay
tzmbl
cell
infect
hivenvpseudotyp
virus
h
cell
wash
extens
remov
supernat
fresh
product
ad
continu
experi
ad
cultur
medium
h
h
h
h
h
h
h
h
infect
maraviroc
mvc
receptor
antagonist
azidothymidin
azt
reversetranscriptas
inhibitor
raltegravir
ral
integras
inhibitor
fusion
inhibitor
sever
control
end
experi
inhibit
viral
replic
measur
luciferas
activ
interact
receptor
assess
flow
cytometri
fac
analysi
briefli
cell
harvest
incub
without
posit
control
min
cell
wash
fac
buffer
stain
pe
antihuman
antibodi
bd
pharmingen
shanghai
china
min
ice
wash
cell
resuspend
fac
buffer
fac
analysi
bd
fac
calibur
flow
cytomet
bd
bioscienc
franklin
lake
nj
usa
cell
apoptosi
pbmc
detect
use
annexin
v
fitc
apoptosi
detect
kit
dojindo
tokyo
japan
pbmc
isol
activ
cona
sigma
day
describ
prestimul
pbmc
incub
fresh
contain
ngml
anoth
day
day
cell
collect
stain
annexinvfitc
propidium
iodid
pi
follow
manufactur
instruct
data
acquir
bd
fac
calibur
flow
cytomet
bd
bioscienc
san
jose
ca
usa
activ
format
sixhelix
bundl
measur
nativ
polyacrylamid
gel
electrophoresi
npage
assay
gener
npeptid
synthes
beij
scilight
biotechnolog
ltd
beij
china
incub
differ
concentr
min
peptid
ad
anoth
min
incub
sampl
mix
trisglycin
nativ
sampl
buffer
load
onto
trisglycin
gel
electrophoresi
v
constant
voltag
min
electrophoresi
gel
stain
coomassi
blue
dye
imag
biorad
gel
doc
xr
imag
system
biorad
hercul
ca
usa
azt
use
neg
control
surfac
plasmon
reson
spr
bind
assay
perform
use
biacor
ge
healthcar
surfac
sensor
chip
activ
inject
nhydroxysuccimid
nh
diethylaminopropyl
carbodiimid
edc
flow
rate
min
peptid
recombin
protein
recombin
protein
dissolv
mm
acet
buffer
ph
respect
immobil
chip
use
amin
coupl
bind
site
block
ethanolaminehcl
ph
inject
direct
bind
assay
dilut
serial
concentr
inject
surfac
peptid
protein
rate
min
competit
assay
incub
solubl
protein
min
prior
inject
mixtur
inject
flow
cell
protein
respect
assay
unmodifi
surfac
use
refer
surfac
reson
unit
valu
ru
measur
data
analysi
equilibrium
constant
dissoci
kd
valu
determin
use
biavalu
softwar
ge
healthcar
inhibitori
effect
revers
transcriptas
rt
measur
use
commerci
colorimetr
assay
roch
berlin
germani
follow
manufactur
instruct
briefli
incub
ng
rt
digoxigeni
dig
biotinlabel
dna
solut
per
reaction
tube
h
mixtur
incub
streptavidin
coat
surfac
micropl
h
extens
wash
diglabel
dna
coincub
peroxidas
conjug
antidigpod
antibodi
h
later
acid
abt
substrat
ad
well
wash
min
incub
absorb
cleav
product
measur
od
nm
percent
inhibit
calcul
compar
inhibitor
control
nevirapin
nvp
use
posit
control
inhibitori
effect
proteas
measur
commerci
fluorimetr
assay
anaspec
fremont
ca
usa
accord
manufactur
instruct
brief
first
incub
proteas
assay
buffer
min
mixtur
incub
proteas
substrat
solut
min
room
temperatur
fluoresc
intens
measur
exem
nm
pepstatin
use
posit
control
inhibitori
effect
integras
process
activ
perform
use
fluoresc
reson
energi
transfer
assay
previous
describ
fusion
integras
kindli
gift
liu
wei
beij
univers
technolog
oligonucleotid
substrat
synthes
sb
genetech
beij
china
sequenc
fam
dabcyl
dna
substrat
dissolv
anneal
buffer
mm
trishcl
mm
nacl
mm
edta
ph
denatur
min
anneal
h
drop
everi
process
reaction
perform
black
solidbottom
plate
briefli
incub
integras
reaction
buffer
dtt
mm
nacl
glycerol
mm
hepe
min
subsequ
pm
substrat
mm
ad
start
reaction
h
incub
fluoresc
intens
measur
exem
nm
multimod
plate
reader
ral
use
posit
control
result
present
mean
standard
deviat
sd
statist
analys
perform
use
graphpad
prism
softwar
evalu
antivir
activ
laboratori
strain
use
tzmbl
cell
cell
correspond
halfmaxim
inhibitori
concentr
valu
summar
tabl
consider
variabl
suscept
viru
subtyp
observ
inhibit
subtyp
b
rel
higher
potenc
show
less
sensit
toward
subtyp
c
tzmbl
cell
cell
replic
widetyp
viru
significantli
inhibit
rang
confirm
inhibit
primari
cell
test
use
pbmc
three
healthi
donor
respect
exhibit
strong
inhibitori
effect
pbmc
figur
tabl
nucleosid
revers
transcriptas
inhibitor
azt
serv
posit
control
exhibit
broad
inhibitori
activ
test
virus
figur
addit
remark
high
potenc
show
low
cytotox
tzmbl
cell
pbmc
even
concentr
higher
effect
dose
figur
tabl
signific
chang
percentag
earli
late
apoptot
cell
seen
pbmc
cell
treatment
figur
figur
furthermor
genotox
effect
monitor
use
mous
bone
marrow
micronucleu
test
figur
tabl
data
show
dose
mgkg
result
mortal
bone
marrow
toxic
moreov
serial
organ
analog
amino
acid
modif
test
use
tzmbl
assay
exhibit
potent
antihiv
activ
figur
thu
power
inhibitor
infect
assess
mode
action
first
conduct
timeofaddit
assay
thoroughli
investig
possibl
target
lifecycl
revers
transcriptas
inhibitor
azt
fusion
inhibitor
integras
inhibitor
raltegravir
inhibitor
maraviroc
mvc
serv
control
ad
tzmbl
cell
differ
time
point
pre
viral
adsorpt
h
viruscel
fusion
h
revers
transcript
h
integr
h
transcript
h
matur
h
cell
collect
h
postinfect
analyz
luciferas
activ
illustr
figur
revers
transcriptas
inhibitor
azt
exhibit
potent
antihiv
activ
h
wherea
ral
began
lose
inhibit
activ
h
inhibitor
mvc
fusion
inhibitor
show
inhibit
h
h
indic
inhibit
earli
step
viru
replic
possibl
viral
entri
process
next
analyz
effect
attach
env
protein
target
cell
compar
env
pseudotyp
vsvg
pseudotyp
viru
infect
use
tzmbl
assay
note
figur
inhibit
abolish
replac
envelop
vsvg
although
differ
inhibit
observ
azt
treat
cell
figur
indic
specif
interact
glycoprotein
surfac
plasmon
resonancebas
competit
assay
perform
immobil
recombin
protein
react
recombin
solubl
protein
solut
note
preincub
caus
substanti
reduct
bind
signal
wherea
bind
directli
suggest
compet
bind
figur
analyz
bind
recombin
protein
use
direct
bind
assay
protein
immobil
chip
run
serial
dilut
averag
kd
valu
interact
use
langmuir
bind
model
figur
elucid
bind
abil
natur
receptor
coincub
cell
stain
cell
antibodi
bind
domain
bind
domain
fac
analysi
reveal
suppress
fluoresc
intens
concentrationdepend
manner
figur
addit
incub
induc
secret
figur
suggest
may
interfer
bind
site
receptor
without
activ
cell
also
compar
effect
util
strain
howev
differ
observ
also
inhibit
bind
specif
monoclon
antibodi
cell
data
shown
suggest
interact
coreceptor
also
perform
nativ
polyacrylamid
gel
electrophoresi
npage
detect
effect
format
shown
npage
figur
c
alon
show
band
net
posit
charg
wherea
alon
show
clear
band
low
posit
gel
lane
mix
new
band
correspond
form
appear
higher
posit
lane
incub
densiti
band
weaken
recoveri
band
observ
lane
addit
azt
reduc
format
lane
data
indic
affect
function
conform
similarli
show
clear
concentrationdepend
bind
affin
peptid
spr
assay
bound
immobil
show
averag
kd
nm
figur
taken
togeth
data
reveal
inhibit
envmedi
entri
block
bind
site
receptor
interact
viral
nhr
examin
abil
inhibit
viral
proteas
revers
transcriptas
integras
pepstatin
nevirapin
nvp
ral
use
posit
control
respect
suppress
proteas
activ
figur
block
revers
transcriptas
activ
figur
integras
process
figur
highest
concentr
maximum
inhibit
rate
revers
transcriptas
integras
process
approxim
respect
data
impli
vitro
reduct
revers
transcriptas
integras
activ
unlik
major
mechan
induc
inhibit
nanomolar
concentr
antivir
activ
pom
first
document
later
extens
studi
influenza
poliovirus
herp
simplex
viru
etc
especi
pom
found
effect
simian
immunodefici
viru
siv
known
antimonium
tungstat
one
firstgener
pom
one
studi
pom
far
progress
clinic
trial
howev
caus
advers
effect
hepat
renal
function
pom
still
suffer
stigma
failur
although
new
gener
pom
includ
keggin
structur
synthes
less
toxic
greater
efficaci
studi
focus
cancer
therapi
studi
conduct
investig
antihiv
potenti
past
decad
mechan
action
remain
unclear
present
work
evalu
potenc
mechan
action
keggin
pom
prevent
entri
replic
demonstr
inhibit
replic
multipl
viru
strain
valu
nanomolar
rang
addit
remark
high
potenc
reveal
low
cytotox
genotox
high
therapeut
index
ti
make
good
candid
treatment
although
antivir
activ
pom
document
mode
antivir
action
remain
elus
previou
studi
demonstr
pom
could
block
revers
transcriptas
rt
proteas
thu
conduct
assay
test
inhibit
rt
proteas
integras
exhibit
certain
degre
inhibit
rt
integras
proteas
also
observ
rt
inhibit
percentag
compar
inhibit
percentag
indic
activ
fulli
mediat
via
inhibit
rt
integras
activ
learn
step
cycl
target
conduct
timedrugaddit
assay
thorough
investig
possibl
target
lifecycl
ad
differ
time
point
show
exhibit
inhibit
earli
step
viru
replic
moreov
specif
interact
envelop
vsvg
thu
viral
entri
process
might
like
antivir
target
envelop
glycoprotein
compos
respons
viru
bind
membran
fusion
first
step
entri
host
cell
involv
bind
envelop
glycoprotein
target
cell
membran
previou
studi
reveal
pom
effect
block
viral
absorpt
interact
glycoprotein
assay
directli
bind
spr
assay
howev
compet
bind
receptor
monomer
protein
compos
four
immunoglobulin
ig
like
extracellular
domain
numer
mutagenesi
test
indic
domain
complementaritydetermin
region
region
critic
bind
block
antibodi
thu
use
antibodi
bind
domain
analyz
interact
cell
membran
fac
analysi
confirm
direct
bind
domain
receptor
interact
coreceptor
transmembran
subunit
experi
conform
chang
ntermin
heptad
repeat
nhr
associ
ctermin
heptad
repeat
chr
form
thermost
sixhelix
bundl
core
nhr
chr
domain
critic
membran
fusion
nhr
chr
deriv
protein
block
core
format
interact
chr
nhr
respect
serv
import
target
hiv
fusion
inhibitor
studi
interf
format
bind
nhr
peptid
kd
valu
bind
close
obtain
cellbas
assay
suggest
inhibit
entri
interf
nhr
disrupt
six
helix
bundl
format
current
antiretrovir
therapi
combin
three
antiretrovir
drug
target
differ
step
life
cycl
despit
fact
reduc
viral
load
undetect
level
greatli
improv
surviv
rate
life
qualiti
hivinfect
patient
still
face
challeng
includ
longterm
drug
resist
unwant
drugdrug
interact
low
complianc
patient
thu
discoveri
multifunct
agent
interact
simultan
one
target
proven
effect
antihiv
lead
discoveri
instanc
induc
cell
kinas
itk
mammalian
target
rapamycin
mtor
inhibitor
block
multistep
hiv
replic
includ
viral
entri
revers
transcript
integr
viral
particl
product
mani
plantderiv
polyphenol
quercetin
isoflavon
flavanon
phenol
acid
deriv
show
activ
variou
viral
enzym
target
simultan
importantli
hiv
proteas
inhibitor
found
affect
virion
releas
also
block
viral
entri
revers
transcript
transcript
present
studi
identifi
multitarget
profil
block
viral
entri
also
interf
main
hiv
enzym
revers
transcriptas
integras
addit
pom
could
easili
modifi
variou
chemic
reaction
enhanc
specif
activ
less
expens
organ
agent
synthes
serial
pom
deriv
decor
amino
acid
improv
biocompat
modif
affect
antivir
activ
thu
shown
promis
properti
drug
develop
also
import
note
pharmacokinet
pharmacodynam
profil
metalbas
compound
yet
identifi
warrant
investig
summari
result
reveal
safe
potent
broad
spectrum
antiretrovir
activ
data
suggest
function
earli
stage
infect
partial
directli
interact
nhr
block
domain
receptor
find
suggest
may
promis
drug
candid
treatment
